JP2024544975A5 - - Google Patents

Info

Publication number
JP2024544975A5
JP2024544975A5 JP2024527868A JP2024527868A JP2024544975A5 JP 2024544975 A5 JP2024544975 A5 JP 2024544975A5 JP 2024527868 A JP2024527868 A JP 2024527868A JP 2024527868 A JP2024527868 A JP 2024527868A JP 2024544975 A5 JP2024544975 A5 JP 2024544975A5
Authority
JP
Japan
Prior art keywords
unsubstituted
substituted
independently
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527868A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544975A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079788 external-priority patent/WO2023086978A2/en
Publication of JP2024544975A publication Critical patent/JP2024544975A/ja
Publication of JP2024544975A5 publication Critical patent/JP2024544975A5/ja
Pending legal-status Critical Current

Links

JP2024527868A 2021-11-15 2022-11-14 分岐した三重脂質修飾核酸化合物 Pending JP2024544975A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163279269P 2021-11-15 2021-11-15
US63/279,269 2021-11-15
PCT/US2022/079788 WO2023086978A2 (en) 2021-11-15 2022-11-14 Branched triple lipid-modified nucleic acid compounds

Publications (2)

Publication Number Publication Date
JP2024544975A JP2024544975A (ja) 2024-12-05
JP2024544975A5 true JP2024544975A5 (cg-RX-API-DMAC10.html) 2025-11-28

Family

ID=86336679

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527868A Pending JP2024544975A (ja) 2021-11-15 2022-11-14 分岐した三重脂質修飾核酸化合物

Country Status (10)

Country Link
US (1) US20250215432A1 (cg-RX-API-DMAC10.html)
EP (1) EP4433063A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024544975A (cg-RX-API-DMAC10.html)
KR (1) KR20240101658A9 (cg-RX-API-DMAC10.html)
CN (1) CN118215485A (cg-RX-API-DMAC10.html)
AU (1) AU2022388810A1 (cg-RX-API-DMAC10.html)
CA (1) CA3235963A1 (cg-RX-API-DMAC10.html)
IL (1) IL312510A (cg-RX-API-DMAC10.html)
MX (1) MX2024005863A (cg-RX-API-DMAC10.html)
WO (1) WO2023086978A2 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026163078A1 (en) 2025-01-29 2026-08-06 Novartis Ag Compounds targeting dmpk for the treatment of myotonic dystrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014205451A2 (en) * 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compositions and methods for modulation of target nucleic acids
EP3603648B1 (en) * 2017-03-29 2025-09-17 Shionogi & Co., Ltd Complex of nucleic acid medicine and multibranched lipid
JP7583712B2 (ja) * 2018-05-30 2024-11-14 ノバルティス アーゲー 脂質修飾された核酸化合物および方法
JP2023503644A (ja) * 2019-11-27 2023-01-31 ディー・ティー・エックス・ファーマ・インコーポレイテッド デュシェンヌ型筋ジストロフィーの治療のための化合物および方法

Similar Documents

Publication Publication Date Title
AU2021201075B2 (en) Novel lipids and compositions for the delivery of therapeutics
CN110072530B (zh) 4′-磷酸酯类似物和包含其的寡核苷酸
JP7748500B2 (ja) トリループを含む二本鎖核酸インヒビター分子
US7053199B2 (en) Nucleoside analogs and oligonucleotide derivatives containing these analogs
JP2023503722A5 (cg-RX-API-DMAC10.html)
JP2023503644A5 (cg-RX-API-DMAC10.html)
US6066447A (en) Modified oligonucleotides
TW202122093A (zh) 化合物、藥物綴合物、試劑盒及其用途
JPH08511002A (ja) ポリヌクレオチド架橋剤としての非ヌクレオシドクマリン誘導体
CN1681814A (zh) 通过1h-咪唑并[4,5-c]喹啉-4-邻苯二甲酰亚胺类中间体制备1h-咪唑并[4,5-c]喹啉-4-胺类化合物
JP2008048741A (ja) 新規な塩基対形成スキームの使用による非特異的ハイブリダイゼーションの減少
EP0688784A2 (de) Neue 3'-Modifizierte Oligonucleotid-Derivate
JPH05505101A (ja) オリゴヌクレオチド療法における三重らせん形成
JP2004537517A5 (cg-RX-API-DMAC10.html)
JP2005519035A5 (cg-RX-API-DMAC10.html)
JP2025038097A (ja) 核酸、薬物組成物及び複合体ならびに調製方法と使用
JP2024536146A5 (cg-RX-API-DMAC10.html)
JP2024543372A5 (cg-RX-API-DMAC10.html)
CA3094008A1 (en) Double-stranded nucleic acid inhibitor molecules modified with tm-increasing nucleotides
JP2025511183A5 (cg-RX-API-DMAC10.html)
EP1142902A2 (de) 3'-Derivatisierte Oligonucleotidanaloga mit nichtnucleotidischen Gruppierungen, deren Herstellung und Verwendung
JPWO2023032995A5 (cg-RX-API-DMAC10.html)
JP7854977B2 (ja) 分子の膜貫通送達のための化合物および方法
US20110130557A1 (en) Intercalating triplexes and duplexes using aryl naphthoimidazol and process for the preparation thereof
DE60225652T2 (de) Oligonukleotidmarkierungsreagenzien auf der Basis von azyklischen Nukleosiden, und deren derivatisierte Konjugate